MAPT and neurodegenerative disease: These new findings represent the successful completion of the initial step for the preclinical evaluation and development of this class of drugs, the 5LO inhibitors, as a novel and potentially disease‐modifying agents for neurodegenerative diseases characterized by the accumulation of highly phosphorylated microtubule‐associated protein tau.